Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
Company profile
Ticker
LLY, LLY-GF, LLY-GM, LLY-SE
Exchange
Website
CEO
David Ricks
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LILLY ELI & CO, LILLY ELI & CO ET AL
SEC CIK
Corporate docs
Subsidiaries
Akouos Securities Corporation • Akouos, Inc. • Alnara Pharmaceuticals, Inc. • Andean Technical Operations • ARMO Biosciences, Inc. • Avid Radiopharmaceuticals, Inc. • CoLucid Pharmaceuticals, Inc. • Compania Farmaceutica Eli Lilly de Centro America S.A. • Dermira, Inc. • DICE Alpha Inc. ...
IRS number
350470950
LLY stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
8 Mar 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Other Events
9 Feb 24
424B2
Prospectus for primary offering
8 Feb 24
FWP
Free writing prospectus
7 Feb 24
424B2
Prospectus for primary offering
7 Feb 24
8-K
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
6 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
22 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
18 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
4 Dec 23
Transcripts
LLY
Earnings call transcript
2023 Q4
6 Feb 24
LLY
Earnings call transcript
2023 Q3
2 Nov 23
LLY
Earnings call transcript
2023 Q2
8 Aug 23
LLY
Earnings call transcript
2023 Q1
27 Apr 23
LLY
Earnings call transcript
2022 Q4
2 Feb 23
LLY
Earnings call transcript
2022 Q3
1 Nov 22
LLY
Earnings call transcript
2022 Q2
4 Aug 22
LLY
Earnings call transcript
2022 Q2
7 Jun 22
LLY
Earnings call transcript
2022 Q1
28 Apr 22
LLY
Earnings call transcript
2021 Q4
3 Feb 22
Latest ownership filings
4
Donald A Zakrowski
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
Gabrielle Sulzberger
21 Feb 24
4
Mary Lynne Hedley
21 Feb 24
4
JUAN R LUCIANO
21 Feb 24
4
KIMBERLY H JOHNSON
21 Feb 24
4
Ralph Alvarez
21 Feb 24
4
Change in insider ownership
20 Feb 24
4
Change in insider ownership
16 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.38 bn | 2.38 bn | 2.38 bn | 2.38 bn | 2.38 bn | 2.38 bn |
Cash burn (monthly) | 104.57 mm | 19.72 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 589.08 mm | 111.07 mm | n/a | n/a | n/a | n/a |
Cash remaining | 1.79 bn | 2.27 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 17.1 | 115.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
53.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2738 |
Opened positions | 336 |
Closed positions | 496 |
Increased positions | 1029 |
Reduced positions | 1029 |
13F shares | Current |
---|---|
Total value | 274.77 tn |
Total shares | 512.59 mm |
Total puts | 1.82 mm |
Total calls | 1.20 mm |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 71.61 mm | $41.74 tn |
PNC PNC Financial Services | 51.71 mm | $30.14 tn |
STT State Street | 33.79 mm | $19.70 tn |
FMR | 32.85 mm | $19.15 tn |
Capital World Investors | 26.95 mm | $15.71 tn |
Primecap Management | 22.20 mm | $12.94 tn |
T. Rowe Price | 21.83 mm | $12.72 bn |
JPM JPMorgan Chase & Co. | 19.27 mm | $11.24 tn |
MS Morgan Stanley | 12.66 mm | $7.38 tn |
Wellington Management | 11.78 mm | $6.87 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Donald A Zakrowski | Common Stock | Sell | Dispose S | No | Yes | 753.6 | 750 | 565.20 k | 7,880 |
15 Feb 24 | Lilly Endowment | Common Stock | Sell | Dispose S | No | No | 762.261 | 1,400 | 1.07 mm | 99,068,494 |
15 Feb 24 | Lilly Endowment | Common Stock | Sell | Dispose S | No | No | 761.558 | 7,863 | 5.99 mm | 99,069,894 |
15 Feb 24 | Lilly Endowment | Common Stock | Sell | Dispose S | No | No | 760.191 | 41,053 | 31.21 mm | 99,077,757 |
12 Feb 24 | Donald A Zakrowski | Common Stock | Grant | Acquire A | No | No | 737.26 | 1,254 | 924.52 k | 8,630 |
12 Feb 24 | Skovronsky Daniel | Common Stock | Grant | Acquire A | No | No | 737.26 | 12,910 | 9.52 mm | 123,738 |
12 Feb 24 | Skovronsky Daniel | RSU Common Stock | Grant | Acquire A | No | No | 0 | 8,989 | 0.00 | 8,989 |
12 Feb 24 | Donald A Zakrowski | RSU Common Stock | Grant | Acquire A | No | No | 0 | 186 | 0.00 | 186 |
12 Feb 24 | Donald A Zakrowski | RSU Common Stock | Grant | Acquire A | No | No | 0 | 184 | 0.00 | 184 |
9 Feb 24 | Lilly Endowment | Common Stock | Sell | Dispose S | No | No | 745.24 | 2,300 | 1.71 mm | 99,118,810 |
News
10 Health Care Stocks Whale Activity In Today's Session
18 Mar 24
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
18 Mar 24
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 20 Years
15 Mar 24
JP Morgan Maintains Overweight on Eli Lilly and Co, Raises Price Target to $850
15 Mar 24
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
14 Mar 24
Press releases
Thinking about trading options or stock in Intuit, Pinterest, Adobe, Eli Lilly, or Robinhood Markets?
14 Mar 24
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
10 Mar 24
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
8 Mar 24
Thinking about buying stock in SoundHound AI, Eli Lilly, Dell Technologies, NKGen Biotech, or Riot Platforms?
6 Mar 24
Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
5 Mar 24